Cell Medica Ltd has completed another stage of its strategy for developing immunotherapies for solid tumours with the acquisition of Delenex Therapeutics AG, an antibody specialist based in Switzer ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Finance, Grants, Deals
